BioXcel Therapeutics Inc (FRA:BX2)
€ 1.892 0.006 (0.32%) Market Cap: 72.49 Mil Enterprise Value: 98.09 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 21/100

BioXcel Therapeutics, Inc. To Discuss Achieved Targeted Exposures of BXCL501 Conference Call Transcript

May 20, 2019 / 12:30PM GMT
Release Date Price: €9.58 (-0.04%)
Operator

Good morning, and welcome to the BioXcel Therapeutics Phase I pharmacokinetic bioavailability and safety study results of BXCL501 conference call and webcast. (Operator Instructions)

I will now turn the conference over to Carol Ruth. Please go ahead, ma'am.

Carol A. Ruth
The Ruth Group, Inc. - Founder, President & CEO

Okay. Thank you, operator. Just to remind everyone, certain matters discussed in today's conference call or answers that may be given to questions as -- are forward-looking statements that are subject to risk and uncertainties relating to future events, including, but not limited to, the advancement and development of BXCL501. Actual results could differ materially than those anticipated in these forward-looking statements.

The risk factors and other uncertainties that may affect results are detailed in our most recent public filings with the SEC, including our quarterly report on Form 10-Q for the quarter period ended March 31, 2019, which can be found on our website,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot